Tengda Construction Group Co.Ltd(600512) won the bid of 479 million yuan rail transit project
According to the announcement of Tengda Construction Group Co.Ltd(600512) , the company won the bid of “civil engineering bid 10 of phase I project of Shanghai rail transit line 21 (Yanggao North Road station ~ Dongjing Road station interval, Dongjing Road station and Gaonan River Bridge)”, and the bid price was 47859999 yuan.
People.Cn Co.Ltd(603000) it is proposed to transfer 100% equity of shuoge technology
People.Cn Co.Ltd(603000) announced that the company plans to publicly list and transfer 100% equity of Beijing shuoge Technology Co., Ltd. (hereinafter referred to as “shuoge technology”) in Beijing property exchange, and the transfer price will not be lower than the equity evaluation value of shuoge technology after filing.
Guangyuyuan Chinese Herbal Medicine Co.Ltd(600771) holding subsidiary Shanxi Guangyuyuan Chinese Herbal Medicine Co.Ltd(600771) temporary shutdown
Guangyuyuan Chinese Herbal Medicine Co.Ltd(600771) announced that Shanxi Guangyuyuan Chinese Herbal Medicine Co.Ltd(600771) , the core holding subsidiary of the company, is located in Taigu District, Jinzhong City, Shanxi Province. Due to the recent local epidemic, Shanxi Guangyuyuan Chinese Herbal Medicine Co.Ltd(600771) has implemented temporary shutdown as required. This temporary shutdown will delay the completion of the production plan and the delivery of finished products on schedule, which will have a certain impact on the market supply.
Nuode Investment Co.Ltd(600110) Sun company signed a major supply contract with an overseas large vehicle enterprise
Nuode Investment Co.Ltd(600110) announced that Huizhou electronics, a wholly-owned subsidiary of the company, signed a production pricing contract for lithium battery copper foil products with an overseas large automobile enterprise, and agreed that the company and its subsidiaries would supply copper foil products to the cooperative customers and their authorized parties from January 1, 2022. In 2022, the company and its wholly-owned subsidiaries promised the cooperative customers that the total supply of products would not be less than 6930 tons. After January 1, 2023, the company and its subsidiaries guarantee to the cooperative customers that the supplied products will not be less than 1515 tons per month.
Beijing-Shanghai High Speed Railway Co.Ltd(601816) performance express: net profit in 2021 increased by 49% year-on-year
Beijing-Shanghai High Speed Railway Co.Ltd(601816) released the performance express. In 2021, the company achieved an operating revenue of 29303637800 yuan, a year-on-year increase of 16.11%; The net profit attributable to the shareholders of the listed company was 4814853200 yuan, a year-on-year increase of 49.12%. The basic earnings per share is 0.098 yuan. The growth of the company’s operating performance is mainly due to the growth of operating revenue. Due to the good situation of epidemic prevention and control, the Feihu section of Hehang high-speed railway of the subsidiary Jingfu Anhui company was opened and operated in June 2020. The passenger traffic volume and the number of trains of the company increased compared with the same period, and the corresponding passenger transportation service revenue and road network service revenue increased.
Hefei Metalforming Intelligent Manufacturing Co.Ltd(603011) shareholders plan to reduce their holdings of no more than 2% of the company’s shares
Hefei Metalforming Intelligent Manufacturing Co.Ltd(603011) announced that CITIC Investment Holdings, a shareholder with a shareholding of 9.04%, plans to reduce its holdings of no more than 10095800 shares of the company by means of centralized bidding within 180 days after 15 trading days from the date of the announcement of this reduction plan, that is, the reduction does not exceed 2% of the total share capital of the company.
Bio-Thera Solutions Ltd(688177) performance express: net profit turns loss into profit in 2021
Bio-Thera Solutions Ltd(688177) released the performance express. In 2021, the company achieved an operating revenue of 828.8315 million yuan, a year-on-year increase of 348.04%; The company realized a net profit of 85.1785 million yuan attributable to the owners of the parent company, which turned losses into profits compared with the same period of last year, with a loss of 51.32265 million yuan in the same period of last year. The basic earnings per share is 0.21 yuan. During the reporting period, the company actively expanded more global market share and reached business cooperation with many enterprises at home and abroad. At the same time, the company actively expanded the Chinese market, gradually expanded the business scale of gelolib (adalimumab injection), and the sales revenue increased steadily.
Juguang technology performance express: net profit in 2021 increased by 94% year-on-year
Ju Guang technology released a performance express. In 2021, the company achieved an operating revenue of 475.8046 million yuan, a year-on-year increase of 32.21%; The net profit attributable to the owners of the parent company was 67.7616 million yuan, a year-on-year increase of 94.33%. During the reporting period, the company’s semiconductor laser business achieved growth in medical and health, advanced manufacturing and other application fields, and actively expanded new businesses such as prefabricated gold tin thin film ceramic heat sink and pan semiconductor process; The shipment volume of the company’s beam collimation conversion series products has increased significantly, and a breakthrough has been made in emerging markets such as light field homogenizer; The development trend of automotive application (LIDAR) business is good. Various projects are advancing in an orderly manner, and the sales revenue is growing steadily.
Jenkem Technology Co.Ltd(688356) performance express: net profit in 2021 increased by 107% year-on-year
Jenkem Technology Co.Ltd(688356) released the performance express. In 2021, the company achieved a total operating revenue of 35.11906 million yuan, a year-on-year increase of 88.18%; The net profit attributable to the owners of the parent company was 176925400 yuan, a year-on-year increase of 106.50%. The basic earnings per share is 2.95 yuan. In 2021, the company’s product sales revenue and technical service revenue increased rapidly; Orders for medical device end products from foreign customers continued to increase steadily.
